New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk
New labeling will suggest STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk.
This is a case of labeling catching up with the evidence.
Bisphosphonates persist in the bones for years, so 3 to 5 years of therapy is enough for many patients.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote